Cabaletta Bio Inc. (CABA)
Company Description
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases.
Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells.
The company's lead product candidate is DSG3-CAART, which is in Phase I clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and Hemophilia A with Factor VIII alloantibodies.
Its product candidate pipeline also includes MuSK-CAART, a preclinical stage product to treat a subset of patients with myasthenia gravis; FVIII-CAART, a discovery stage product to treat a subset of patients with Hemophilia A; and DSG3/1-CAART, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris.
It has a collaboration with the University of Pennsylvania; and research agreement with The Regents of the University of California.
The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018.
Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Country | United States |
IPO Date | Oct 25, 2019 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 161 |
CEO | Dr. Steven A. Nichtberger M.D. |
Contact Details
Address: 2929 Arch Street Philadelphia, Pennsylvania United States | |
Website | https://www.cabalettabio.com |
Stock Details
Ticker Symbol | CABA |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001759138 |
CUSIP Number | 12674W109 |
ISIN Number | US12674W1099 |
Employer ID | 00-0000000 |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Dr. Steven A. Nichtberger M.D. | Co-Founder, Chairman, Chief Executive Officer & President |
Dr. Aimee Payne M.D., Ph.D. | Co-Founder & Co-Chair of Scientific Advisory Board |
Dr. Gwendolyn K. Binder Ph.D. | President of Science & Technology |
Dr. Michael C. Milone M.D., Ph.D. | Co-Founder & Co-Chair of Scientific Advisory Board |
Dr. Samik Basu M.D. | Chief Scientific Officer |
Gerwin Winter M.B.A., Pharm.D. | SVice President & Head of International |
Heather Harte-Hall M.Sc. | Chief Compliance Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 31, 2025 | S-8 | Filing |
Mar 31, 2025 | POS AM | Filing |
Mar 31, 2025 | 10-K | Annual Report |
Mar 31, 2025 | POSASR | Filing |
Mar 31, 2025 | 8-K | Current Report |
Mar 04, 2025 | 4 | Filing |
Mar 04, 2025 | 4 | Filing |
Mar 04, 2025 | 4 | Filing |
Mar 04, 2025 | 4 | Filing |
Mar 04, 2025 | 4 | Filing |